CVS Health to Restore Coverage of Eli Lilly's Weight Loss Drugs
Decision Affects Zepbound and Newly Approved Foundayo, Impacting Competition with Novo Nordisk
Auf einen Blick
- CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound on Oct.
- 1 and add coverage of its new obesity pill Foundayo on June 1, making both GLP-1 medications co-preferred options on its standard commercial formulary, affecting 25-30 million Americans and boosting Lilly's market position against Novo Nordisk.
KI-generierte Zusammenfassung
Warum es wichtig ist
CVS Health's move to cover Eli Lilly's weight loss drugs comes after a previous deal with Novo Nordisk, aiming to increase competition and affordability in the GLP-1 market.
CVS Health on Thursday said it will restore coverage of Eli Lilly's blockbuster weight loss injection Zepbound and start covering its new obesity pill Foundayo on its standard drug plans – a win for the drugmaker and certain patients who will be able to access more treatment options. [...] As a pharmacy benefit manager, Caremark is hired by employers, government entities, unions and other health plans to negotiate the cost of medications included on formularies chosen by plan sponsors. [...] CVS said Caremark will ensure a "smooth transition" to covered therapies for customers, consultants, providers and members.
Worauf zu achten ist
KI-Ausblick — Möglichkeiten, keine Fakten
Increased competition may lead to pricing adjustments in the weight loss drug market.
Wahrscheinlich · Innerhalb von Wochen
Other PBM's may follow suit in adjusting formulary coverage for GLP-1 drugs.
Möglich · Innerhalb von Monaten
Offene Fragen
- Long-term impact on drug pricing negotiations
- Exact terms of the agreements with Lilly and Novo Nordisk
